Q4 2025 Ionis Pharmaceuticals Inc Earnings Call Transcript
Key Points
- Ionis Pharmaceuticals Inc (IONS) successfully launched two independent products, TRYNGOLZA and DAWNZERA, with strong market performance.
- The company reported a 34% increase in revenue year-over-year, driven by both commercial products and R&D collaborations.
- Olezarsen received breakthrough therapy designation from the FDA, with promising Phase III results for severe hypertriglyceridemia.
- The company is on track for multiple additional product launches and late-stage data readouts in 2026, indicating a robust pipeline.
- Ionis Pharmaceuticals Inc (IONS) is well-positioned to achieve cash flow breakeven by 2028, supported by strong financial management and strategic investments.
- The company anticipates a meaningful decline in TRYNGOLZA revenues ahead of the sHTG launch, which could impact short-term financial performance.
- There is uncertainty regarding the FDA's decision on priority review for olezarsen, which could affect the timing of its market entry.
- Pricing dynamics in the market are evolving, potentially impacting the competitive positioning of Ionis Pharmaceuticals Inc (IONS)'s products.
- The company faces competition in the FCS market, which could affect TRYNGOLZA's market share and revenue growth.
- Ionis Pharmaceuticals Inc (IONS) projects a non-GAAP operating loss between $500 million and $550 million for 2026, indicating ongoing financial challenges.
Good morning, and welcome to Ionis's fourth quarter and full year 2025 financial results conference call. As a reminder, this call is being recorded. At this time, I would like to turn the call over to Wade Walke, Senior Vice President of Investor Relations, to lead off the call. Please begin.
Thank you, Keith. Before we begin, I encourage everyone to go to the Investors section of the Ionis website to view the press release and related financial tables we will be discussing today, including a reconciliation of GAAP to non-GAAP financials. We believe non-GAAP financial results better represent the economics of our business and how we manage our business. We've also posted slides on our website to accompany today's call.
With me on the call this morning are Brett Monia, our Chief Executive Officer; Holly Kordasiewicz, Chief Development Officer; Kyle Jenne, Chief Global Product Strategy Officer; and Beth Hougen, Chief Financial Officer. Eugene Schneider, Chief Clinical
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
